Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
about
Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT)MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerCombination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397)Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysisComparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis.Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.Analysis of Prostate Deformation during a Course of Radiation Therapy for Prostate Cancer.Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancerIntravesical Glycosaminoglycan Replacement with Chondroitin Sulphate (Gepan(®) instill) in Patients with Chronic Radiotherapy- or Chemotherapy-Associated CystitisSimultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study.Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.Analysis of late toxicity associated with external beam radiation therapy for prostate cancer with uniform setting of classical 4-field 70 Gy in 35 fractions: a survey study by the Osaka Urological Tumor Radiotherapy Study Group.Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer.Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-upThe curative management of synchronous rectal and prostate cancerAdaptive radiation therapy for prostate cancer.Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.Use of a prospective cohort study in the development of a bladder scanning protocol to assist in bladder filling consistency for prostate cancer patients receiving radiation therapy.Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for prostate cancerAcute toxicity in prostate cancer patients treated with and without image-guided radiotherapy.Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel.Preclinical investigations towards the first spacer gel application in prostate cancer treatment during particle therapy at HIT.Assessment of interfractional prostate motion in patients immobilized in the prone position using a thermoplastic shellLate gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).Total abdominal irradiation exposure impairs cognitive function involving miR-34a-5p/BDNF axis.Safety and feasibility of prostate stereotactic ablative radiotherapy using multimodality imaging and flattening filter free.The potential failure risk of the cone-beam computed tomography-based planning target volume margin definition for prostate image-guided radiotherapy based on a prospective single-institutional hybrid analysis.Association between rectal bleeding and the absolute dose volume of the rectum following image-guided radiotherapy for patients with prostate cancer.
P2860
Q21203119-70FC0B3F-8A0C-438F-BF60-C344C934F08EQ28478930-F4AE37A9-FF43-440C-9D36-C329A7710CAFQ31133958-DB741B23-1A89-4B50-8761-E79FC0E83D0FQ31159825-A3AF5D80-D938-4538-8AA3-910E8B3A7E66Q33613683-CFBA4FC9-CD59-4BEC-B9BC-EA105F813656Q33626084-D2E5F048-FB6F-4583-900C-EC3C1D68EC8FQ33823063-2839F3C1-CC03-45CC-9025-802EBDEC0332Q35676937-FA5B08A0-6AE0-4999-B81F-215884904101Q35847743-443E47E1-B2B4-4CD2-BACB-B061094F09F3Q35901614-C7EFA7FA-DB72-4ADE-B1DE-D540072C7805Q36138138-00202F22-B83B-45F1-89F4-C58A0D88E371Q36396456-69717D86-0BBE-4622-8E48-9F5A4847BE88Q36500061-D5A5A645-A734-4C0C-A017-49FB2CFBFEFBQ36843615-8538D0F9-DC0C-46AC-9364-E60C553DCE90Q37081939-D94ABBAD-DC67-4D8C-98BE-79662D3C927BQ37177795-6EDCE578-59EC-498D-A214-FF6EB0E32142Q37706798-CE32EFD4-40F5-49A1-8A13-25A01F001C9FQ38226822-CC363C0E-8FEB-4A0B-8AD5-98C92AE198ADQ38959424-0142BFDF-782D-41C7-9F51-3C89606AAE27Q38981805-95BA7EFA-B255-4284-9A1C-79E73C80C264Q39135519-593AF0B6-2B53-4065-B73C-E474DBE00AECQ39701751-FBC79E3E-40CD-4376-BB8F-4556AEE0AB12Q41384091-4E5CE454-8BA2-4E9A-8B80-3737E203910BQ41859459-2CB7FE7A-33ED-47DE-A254-6FC745CB54E9Q41915918-F02B0EB1-9A35-4441-A60D-211A1DF68322Q48216728-7BD0351C-DB8D-4066-BFDA-D5BB2B17FF5BQ48233697-01E88438-6B29-49DB-96D2-D015F982AC61Q55479788-B232E841-9A57-4F32-B66A-CF2DFCAF3676Q55663443-7D9173AF-361E-4208-B33D-EB41EEFD887F
P2860
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Phase III pilot study of dose ...... PSA control and side effects.
@ast
Phase III pilot study of dose ...... PSA control and side effects.
@en
type
label
Phase III pilot study of dose ...... PSA control and side effects.
@ast
Phase III pilot study of dose ...... PSA control and side effects.
@en
prefLabel
Phase III pilot study of dose ...... PSA control and side effects.
@ast
Phase III pilot study of dose ...... PSA control and side effects.
@en
P2093
P2860
P356
P1476
Phase III pilot study of dose ...... PSA control and side effects.
@en
P2093
A Warrington
C M Nutting
D Lawrence
D P Dearnaley
R A Huddart
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602301
P407
P577
2005-02-01T00:00:00Z